Drug intelligence / Profile preview

NKL-001

Development stage: Preclinical
Lead developer: NKILT Therapeutics
Modality: Small Molecules, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

NKL-001 is a preclinical-stage pharmaceutical drug developed by NKILT Therapeutics. It is an inhibitor of HLA-G (human leukocyte antigen G), a non-classical major histocompatibility complex (MHC) class I molecule implicated in immune evasion by tumors. By inhibiting HLA-G, NKL-001 aims to enhance anti-tumor immune responses, particularly through the activation of natural killer (NK) cells and other components of the immune system. The primary indications under investigation are multiple myeloma and acute myeloid leukemia[2].

Targets

HLA-G (Human leukocyte antigen G)

Beyond the preview

Go deeper on NKL-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKL-001.

Explore the full profile